Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Flexion Therapeutics, Inc is a drug manufacturers-specialty & generic business based in the US. Flexion Therapeutics shares (FLXN) are listed on the NASDAQ and all prices are listed in US Dollars. Flexion Therapeutics employs 257 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$8.37|
|52-week range||$5.84 - $13.78|
|50-day moving average||$7.92|
|200-day moving average||$9.48|
|Wall St. target price||$19.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-4.28|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-07-25)||N/A|
|1 month (2021-07-02)||4.89%|
|3 months (2021-05-05)||12.20%|
|6 months (2021-02-01)||N/A|
|1 year (2020-08-01)||N/A|
|2 years (2019-08-01)||N/A|
|3 years (2018-08-01)||N/A|
|5 years (2016-08-01)||N/A|
|Revenue TTM||$90 million|
|Gross profit TTM||$66.5 million|
|Return on assets TTM||-24.02%|
|Return on equity TTM||-6256.74%|
|Market capitalisation||$293.2 million|
TTM: trailing 12 months
There are currently 7.1 million Flexion Therapeutics shares held short by investors – that's known as Flexion Therapeutics's "short interest". This figure is 2% up from 7.0 million last month.
There are a few different ways that this level of interest in shorting Flexion Therapeutics shares can be evaluated.
Flexion Therapeutics's "short interest ratio" (SIR) is the quantity of Flexion Therapeutics shares currently shorted divided by the average quantity of Flexion Therapeutics shares traded daily (recently around 654793.29660239). Flexion Therapeutics's SIR currently stands at 10.89. In other words for every 100,000 Flexion Therapeutics shares traded daily on the market, roughly 10890 shares are currently held short.
However Flexion Therapeutics's short interest can also be evaluated against the total number of Flexion Therapeutics shares, or, against the total number of tradable Flexion Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Flexion Therapeutics's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Flexion Therapeutics shares in existence, roughly 140 shares are currently held short) or 0.1494% of the tradable shares (for every 100,000 tradable Flexion Therapeutics shares, roughly 149 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Flexion Therapeutics.
Find out more about how you can short Flexion Therapeutics stock.
We're not expecting Flexion Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Flexion Therapeutics's shares have ranged in value from as little as $5.84 up to $13.78. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Flexion Therapeutics's is 1.3792. This would suggest that Flexion Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Flexion Therapeutics, Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) knee pain. It is also involved in the development of FX201, a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, a NaV1. 7 inhibitor for the management of post-operative pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts. .
Everything we know about the Chobani IPO, plus information on how to buy in.
Everything we know about the Stronghold Digital Mining IPO, plus information on how to buy in.
Everything we know about the ROX Financial LP IPO, plus information on how to buy in.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.